Cited by 369Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsDrug-Induced Hepatotoxicity and Protection

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., Perrillo, R. P.·2004·Alimentary Pharmacology & Therapeutics

DOI 10.1111/j.1365-2036.2004.02025.x

Open this paper in CoChat — free account

Abstract

BACKGROUND: Insulin sensitizing agents may be useful in treatment of non-alcoholic fatty liver disease. AIM: A pilot study to evaluate the efficacy and safety of metformin in non-alcoholic fatty liver disease. METHODS: In an open labelled study, patients with histologically confirmed non-alcoholic fatty liver disease were given metformin (20 mg/kg) for 1 year. Insulin resistance (by log homeostasis assessment model analysis for insulin resistance and Quantitative Insulin Sensitivity Check Index) and post-treatment hepatic histology were compared with pre-treatment histology. RESULTS: Fifteen patients completed 1 year of treatment. During the initial 3 months, there was improvement in alanine aminotransferase and aspartate aminotransferase (P-value 0.01 and 0.02, respectively) along with improvement in insulin sensitivity. However, after 3 months, there was no further improvement in insulin sensitivity and there was gradual rise in aspartate aminotransferase and alanine aminotransferase back to pre-treatment levels. Among the 10 patients with post-treatment biopsy, three (33%), showed improvement in steatosis, two (20%) showed improvement in inflammation score and one (10%) showed improvement in fibrosis. CONCLUSION: Metformin treatment was associated with only a transient improvement in liver chemistries. A progressive, sustainable reduction in insulin sensitivity was not noted during treatment.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.02025.x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Steatohepatitis
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Metformin
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726

Show all 37 references

Research works printed but not linked: 1

10.1002/hep.1840380427 · DOI

Sorted by citations

Items 101–200 of 366

Insulin sensitizers for the treatment of non-alcoholic fatty liver disease
Öztürk, Z. A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i4.199 · Cited by 76
Metformin prevents endotoxin-induced liver injury after partial hepatectomy
Bergheim, I., Luyendyk, J. P., Steele, C., Russell, G. K., Guo, L., Roth, R. A., & Arteel, G. E. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092122 · Cited by 75
Non-alcohol fatty liver disease in Asia: Prevention and planning
Ashtari, S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i13.1788 · Cited by 74
How should we manage patients with non‐alcoholic fatty liver disease in 2007?
Chan, H. L., de Silva, H. J., Leung, N. W. Y., Lim, S. G., Farrell, G. C., & NAFLD, T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04977.x · Cited by 74
Hepatic Complications of Obesity
Diehl, A. M. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.12.001 · Cited by 76
Self-citation
Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms
Wu, M., Xu, H., Liu, J., Tan, X., Wan, S., Guo, M., Long, Y., & Xu, Y. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6673525 · Cited by 76
Type 2 diabetes in younger adults: the emerging UK epidemic
Wilmot, E. G., Davies, M. J., Yates, T. E., Benhalima, K., Lawrence, I. G., & Khunti, K. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.100917 · Cited by 72
Nonalcoholic fatty liver disease as a component of the metabolic syndrome
Khashab, M. A., Liangpunsakul, S., & Chalasani, N. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0012-0 · Cited by 71
Hypertension and fatty liver: guilty by association?
Brookes, M., & Cooper, B. T. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002148 · Cited by 67
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions
Gerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El‐Demerdash, E. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119220 · Cited by 76
Nonalcoholic Fatty Liver Disease
Paredes, A. H., Torres, D. M., & Harrison, S. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.005 · Cited by 72
Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
Arab, J. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12182 · Cited by 66
Chemical and pharmacological research on the polyphenol acids isolated from Danshen: A review of salvianolic acids
Du, G., Song, J., Du, L., Li, Z., Qiang, G., Wang, S., Yang, X., & Fang, L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.004 · Cited by 67
Review article: drug therapy for non‐alcoholic fatty liver disease
Comar, K. M., & Sterling, R. K. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02751.x · Cited by 65
Non-alcoholic Steatohepatitis in Children
Roberts, E. A. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.008 · Cited by 64
Treatment strategies in nonalcoholic fatty liver disease
Tilg, H., & Kaser, A. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0116 · Cited by 63
Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management
Rafiq, N., & Younossi, Z. M. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.02.009 · Cited by 62
Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome
Rahimi, R. S., & Landaverde, C. E. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533612470464 · Cited by 60
Lifestyle Modification as the Primary Treatment of NASH
Neuschwander‐Tetri, B. A. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.006 · Cited by 62
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2013 · Cited by 59
Alpha-lipoic acid induces adipose triglyceride lipase expression and decreases intracellular lipid accumulation in HepG2 cells
Kuo, H.-T., Lin, T.-H., Chen, W.-L., & Lee, H.-M. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.07.028 · Cited by 57
The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial
Razavizade, M., Jamali, R., Arj, A., Matini, S. M., Moraveji, A., & Taherkhani, E. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.9270 · Cited by 59
Effects of Metformin and Weight Loss on Serum Alanine Aminotransferase Activity in the Diabetes Prevention Program
Krakoff, J. A., Clark, J. M., Crandall, J. P., Wilson, C., Molitch, M. E., Brancati, F. L., Edelstein, S. L., & Knowler, W. C. (2010) · Obesity · doi:10.1038/oby.2010.21 · Cited by 58
Invitro studies and evaluation of metformin marketed tablets-Malaysia
Chandrasekaran, A. R., Jia, C. Y., Theng, C. S., Muniandy, T., Muralidharan, S., & Arumugam, S. (2011) · Cited by 55
Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes
Lingvay, I., Raskin, P., & Szczepaniak, L. S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.02.005 · Cited by 55
Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas
Liu, Y.-C. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i14.2161 · Cited by 53
Salvianolic Acid A Prevents the Pathological Progression of Hepatic Fibrosis in High-Fat Diet-Fed and Streptozotocin-Induced Diabetic Rats
Qiang, G., Yang, X., Qi, X., Shi, L., Zhang, H., Chen, B., Li, X., Zu, M., Zhou, D., Guo, J., et al. (2014) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x14500748 · Cited by 53
The Multifaceted Associations of Hepatobiliary Disease and Diabetes
Bell, D. S. H., & Allbright, E. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.300 · Cited by 51
Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas
Liu, Y., Shen, C., Wu, H., Hsieh, T., Chan, D., Chen, C., Yu, J., Yu, C., Harn, H., Chen, P., et al. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i14.2168 · Cited by 50
Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism
Rouabhia, S., Milić, N., & Abenavoli, L. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.894880 · Cited by 49
Current and Emerging Therapies in Nonalcoholic Fatty Liver Disease
Kashi, M., Torres, D., & Harrison, S. D. (2008) · Seminars in liver disease (Print) · doi:10.1055/s-0028-1091984 · Cited by 54
Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
Doycheva, I., & Loomba, R. S. (2014) · Advances in Therapy · doi:10.1007/s12325-013-0084-6 · Cited by 50
GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
Liu, J., Wang, G., Jia, Y., & Xu, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2580 · Cited by 48
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Prat, L. I., & Tsochatzis, E. A. (2018) · HORMONES · doi:10.1007/s42000-018-0021-9 · Cited by 46
Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
Pan, C. S., & Stanley, T. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00070 · Cited by 48
Treatment regimens for non-alcoholic fatty liver disease
Lam, B. P., & Younossi, Z. M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31827-7 · Cited by 45
Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management
Jichitu, A., BUNGAU, S. G., Stănescu, A. M. A., Vesa, C. M., Toma, M. M., Bustea, C., Iurciuc, S., Rus, M., Bacalbaşa, N., & Diaconu, C. C. (2021) · Diagnostics · doi:10.3390/diagnostics11040689 · Cited by 47
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance
Armandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 47
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes
Qiang, G., Zhang, L., Yang, X., Qi, X., Shi, L., Zhang, H., Chen, B., Li, X., Zu, M., Zhou, D., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.04.028 · Cited by 43
Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges
Xiao, J., Guo, R., Fung, M., Liong, E. C., & Tipoe, G. L. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60021-1 · Cited by 44
Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat
Raso, G. M., Esposito, E., Iacono, A., Pacilio, M., Cuzzocrea, S., Canani, R. B., Calignano, A., & Meli, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.013 · Cited by 41
Essential phospholipids as a supportive adjunct in the management of patients with NAFLD
Dajani, A. I., Hammour, A. M. A., Zakaria, M. A., Jaberi, M. R. A., Nounou, M., & Semrin, A. I. M. (2015) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2015.09.001 · Cited by 40
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview
Dajani, A. I., & Abu-Hammour, A. (2016) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.178527 · Cited by 41
Nonalcoholic Fatty Liver Disease in Children
Mager, D. R., & Roberts, E. A. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2005.10.007 · Cited by 39
Nonalcoholic fatty liver disease in children living in the obeseogenic society
A‐Kader, H. H. (2009) · World Journal of Pediatrics · doi:10.1007/s12519-009-0048-8 · Cited by 39
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis
Le, T., & Loomba, R. S. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/s0973-6883(12)60104-2 · Cited by 41
Medical Treatment of Non-alcoholic Steatohepatitis
Kadayıfçı, A., Merriman, R. B., & Bass, N. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.001 · Cited by 38
Metformin improves nonalcoholic fatty liver disease in db/db mice by inhibiting ferroptosis
Zhang, T., Wang, M.-Y., Wang, G., Lv, Q.-Y., Huang, Y.-Q., Zhang, Y., Wang, W., Zhang, Y., Bai, Y., & Guo, L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176341 · Cited by 40
Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives
Federico, A., Trappoliere, M., & Loguercio, C. (2006) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.04.009 · Cited by 38
Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers
Kwan, H. Y., Niu, X., Dai, W., Tong, T., Chao, X., Su, T., Chan, C. L., Lee, K. C., Fu, X., Hua, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep09114 · Cited by 38
Review article: the treatment of non‐alcoholic steatohepatitis with thiazolidinediones
Reynaert, H., Geerts, A. E., & Henrion, J. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02682.x · Cited by 38
Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
Nakajima, K. (2012) · International Journal of Hepatology · doi:10.1155/2012/950693 · Cited by 37
Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease
Ong, J. P., & Younossi, Z. M. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2005.07.002 · Cited by 37
Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety
Mills, E. P., Brown, K. P. D., Smith, J. D., Vang, P. W., & Trotta, K. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817741852 · Cited by 38
AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells
Lv, Q., Zhen, Q., Liu, L., Gao, R., Yang, S., Huang, Z., Goswami, R., & Li, Q. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.03.003 · Cited by 37
Randomized, Vitamin E-Controlled Trial of Bicyclol Plus Metformin in Non-Alcoholic Fatty Liver Disease Patients with Impaired Fasting Glucose
Han, Y., Shi, J., Ma, A., Xu, Y., Ding, X., & Fan, J. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0136-3 · Cited by 37
Metformin and the Liver: Unlocking the Full Therapeutic Potential
Perazza, F., Leoni, L., Colosimo, S., Musio, A., Bocedi, G., D’Avino, M., Agnelli, G., Nicastri, A., Rossetti, C., Sacilotto, F., et al. (2024) · Metabolites · doi:10.3390/metabo14040186 · Cited by 39
An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)
Lomonaco, R., Chen, J., & Cusi, K. J. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811419157 · Cited by 37
Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase
Samala, N. R., Tersey, S. A., Chalasani, N., Anderson, R. M., & Mirmira, R. G. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.07.014 · Cited by 36
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Snyder, H. S., Sakaan, S. A., March, K. L., Siddique, O., Cholankeril, R. T., Cummings, C. D., Gadiparthi, C., Satapathy, S. K., Ahmed, A., & Cholankeril, G. T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00050 · Cited by 37
Non-alcoholic fatty liver disease in the Philippines:Comparable with other nations?
Lusong, M. A. D. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.913 · Cited by 36
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 35
Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis
Clarke, J., Dzierlenga, A. L., Nelson, N. R., Li, H., Werts, S. J., Goedken, M. J., & Cherrington, N. J. (2015) · Diabetes · doi:10.2337/db14-1947 · Cited by 34
Effect of carnitine‐orotate complex on glucose metabolism and fatty liver: A double‐blind, placebo‐controlled study
Hong, E. S., Kim, E. K., Kang, S. M., Khang, A. R., Choi, S. H., Park, K. S., Jang, H. C., & Lim, S. K. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12536 · Cited by 34
Nonalcoholic fatty liver disease and cardiovascular disease risk
Schindhelm, R. K., Diamant, M., & Heine, R. J. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0030-6 · Cited by 33
Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints
Buckley, A. J., Thomas, E. L., Lessan, N. G., Trovato, F. M., Trovato, G. M., & Taylor-Robinson, S. D. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.08.011 · Cited by 34
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
Chung, W., Promrat, K., & Wands, J. R. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i9.533 · Cited by 35
Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study
Huang, K., Lee, C., Cheng, Y., Gau, S., Tsai, T., Chung, N.-J., & Lee, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1027484 · Cited by 33
Nonalcoholic fatty liver disease (NAFLD): Approach in the adolescent patient
Roberts, E. A., & Yap, J. Y. K. (2006) · Current Treatment Options in Gastroenterology · doi:10.1007/bf02738532 · Cited by 31
Treating nonalcoholic fatty liver disease
Méndez‐Sánchez, N., Arrese, M. A., Zamora‐Valdés, D., & Uribe, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01567.x · Cited by 31
Pharmacologic Therapy of Non-Alcoholic Steatohepatitis
Ratziu, V., & Zelber‐Sagi, S. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.001 · Cited by 30
The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Assi, R. A., Abdulbaqi, I. M., & Chan, S. Y. (2021) · Pharmaceuticals · doi:10.3390/ph14030215 · Cited by 33
Nonalcoholic Hepatic Steatosis in Zucker Diabetic Rats: Spontaneous Evolution and Effects of Metformin and Fenofibrate
Forcheron, F., Abdallah, P., Basset, A., del Carmine, P., Haffar, G., & Beylot, M. (2009) · Obesity · doi:10.1038/oby.2008.661 · Cited by 30
Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
Gitto, S., Vitale, G., Villa, E., & Andreoné, P. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/732870 · Cited by 30
Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?
Green, C., Marjot, T., Tomlinson, J., & Hodson, L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13592 · Cited by 29
Plasmodium Infection Induces Dyslipidemia and a Hepatic Lipogenic State in the Host through the Inhibition of the AMPK-ACC Pathway
Kluck, G. E. G., Wendt, C., Império, G. E., de Araujo, M. F. C., Atella, T. C., Rocha, I. P. G., de Miranda, K. R., & Atella, G. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-51193-x · Cited by 30
Evidence for AMPK-dependent regulation of exocytosis of lipoproteins in a model liver cell line
Puljak, L., Parameswara, V., Dolovcak, S., Waldrop, S. L., Emmett, D. S., Esser, V., Fitz, J., & Kilic, G. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.03.002 · Cited by 29
Is liver disease a threat to patients with metabolic disorders?
Marchesini, G., Forlani, G., & Bugianesi, E. (2005) · Annals of Medicine · doi:10.1080/07853890510011445 · Cited by 28
Nonalcoholic Fatty Liver Disease and Insulin Resistance in Youth
Bloomgarden, Z. T. (2007) · Diabetes Care · doi:10.2337/dc07-zb06 · Cited by 28
Hepatic Complications of Obesity
Diehl, A. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.12.012 · Cited by 28
Self-citation
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review
Chávez-Tapia, N. C. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i48.7826 · Cited by 28
Recent developments in capsule endoscopy
Galmiche, J. P., Coron, E., & Sacher‐Huvelin, S. (2008) · Gut · doi:10.1136/gut.2007.127852 · Cited by 27
Management of nonalcoholic fatty liver disease in the Middle East
Sanai, F. M., Abaalkhail, F. A., Hasan, F. A., Farooqi, M. H., Alnahdi, N., & Younossi, Z. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i25.3528 · Cited by 26
Negative regulation of TGF-β by AMPK and implications in the treatment of associated disorders
Gao, J., Ye, J., Ying, Y., Lin, H., & Luo, Z. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy028 · Cited by 28
State of the art
Pearlman, M. Y., & Loomba, R. S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000060 · Cited by 25
Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens
Chen, W.-L., Wei, H., Chiu, W.-Z., Kang, C.-H., Lin, T.-H., Hung, C., Chen, M., Shieh, M.-S., Lee, C.-C., & Lee, H.-M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.029 · Cited by 25
Emerging drugs for non-alcoholic fatty liver disease
Federico, A., Niosi, M., Blanco, C. D. V., & Loguercio, C. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.1.145 · Cited by 25
Metformin reduces cellular lysophosphatidylcholine and thereby may lower apolipoprotein B secretion in primary human hepatocytes
Wanninger, J., Neumeier, M., Weigert, J., Liebisch, G., Weiß, T. S., Schäffler, A., Aslanidis, C., Schmitz, G., Schölmerich, J., & Buechler, C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.04.012 · Cited by 26
The treatment of NAFLD.
Trappoliere, M., Tuccillo, C., Federico, A., Di Leva, A., Niosi, M., D’Alessio, C., Capasso, R., Coppola, F., D’Auria, M. V., & Loguercio, C. (2005) · PubMed · Cited by 25
Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment
McAvoy, N. C., Ferguson, J., Campbell, I. W., & Hayes, P. C. (2006) · The British Journal of Diabetes · doi:10.1177/14746514060060060201 · Cited by 26
Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study
Riley, P., Sudarshi, D., Johal, M., Benedict, A., Panteli, J. V., Crook, M. A., & O’Donohue, J. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01666.x · Cited by 24
Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease
Ekta, Gupta, M., Kaur, A., Singh, T. G., & Bedi, O. (2020) · Inflammation Research · doi:10.1007/s00011-020-01373-7 · Cited by 26
Nonalcoholic fatty liver disease as a feature of the metabolic syndrome.
Socha, P., Wierzbicka, A., Neuhoff-Murawska, J., Włodarek, D., Podleśny, J., & Socha, J. (2007) · PubMed · Cited by 24
Nonalcoholic Fatty Liver Disease
Sanyal, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.014 · Cited by 53
Review: Advances in the treatment of nonalcoholic fatty liver disease
Mehta, S. R. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810379587 · Cited by 24
Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin
Freemark, M. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00429.x · Cited by 23
Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Zhang, R., Cheng, K., Xu, S., Li, S., Zhou, Y., Zhou, S., Kong, R., Li, L., Li, J., Feng, J., et al. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/8491742 · Cited by 21
Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 21
Drug-Induced Liver Injury
Bonkovsky, H. L., Jones, D. P., Russo, M. W., & Shedlofsky, S. I. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00025-5 · Cited by 22
Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.
Stengel, J. Z., & Harrison, S. A. (2006) · Europe PMC (PubMed Central) · Cited by 20

Authors: Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P.
Affiliations: Ochsner Medical Center (US)
Johns Hopkins University (US)
Corresponding author: Nair, S.
ORCID: Nair, S.
Diehl, A. M.
Venue: Alimentary Pharmacology & Therapeutics
Publisher: Wiley
Published: 2004-06-14
Volume: 20
Issue: 1
Pages: 23-28
ISSN: 0269-2813 (ISSN-L)
1365-2036
DOI: 10.1111/j.1365-2036.2004.02025.x
OpenAlex: W2056505063
Cited by: 369
References: 37
Citations by year: 2026: 1 · 2025: 3 · 2024: 13 · 2023: 13 · 2022: 7 · 2021: 10 · 2020: 9 · 2019: 6 · 2018: 14 · 2017: 13 · 2016: 9 · 2015: 22 · 2014: 21 · 2013: 21 · 2012: 17
FWCI: 20.68
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alimentary Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords: metformin, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin sensitizers, insulin resistance, HOMA-IR, QUICKI, hepatic steatosis, liver fibrosis, liver inflammation, alanine aminotransferase, aspartate aminotransferase, drug safety and efficacy
MeSH terms: Alanine Transaminase, Aspartate Aminotransferases, Drug Evaluation, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Patient Compliance, Pilot Projects, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks